- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/16 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
Patent holdings for IPC class C07D 217/16
Total number of patents in this class: 189
10-year publication summary
|
18
|
11
|
15
|
17
|
10
|
12
|
11
|
12
|
6
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eli Lilly and Company | 4039 |
10 |
| Ardelyx, Inc. | 115 |
8 |
| Abbvie Inc. | 1842 |
6 |
| Tongli Biomedical Co., Ltd | 30 |
6 |
| Ctxt Pty Ltd | 58 |
6 |
| Astellas Pharma Inc. | 1030 |
5 |
| Epizyme, Inc. | 357 |
5 |
| Novartis AG | 10345 |
4 |
| Envista | 4 |
4 |
| Merck Sharp & Dohme Corp. | 2184 |
3 |
| Janssen Pharmaceutica N.V. | 3234 |
3 |
| Forma Therapeutics, Inc. | 155 |
3 |
| Mitsubishi Tanabe Pharma Corporation | 429 |
3 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3263 |
3 |
| Zhejiang University | 3366 |
3 |
| Cytosinlab Therapeutics Co., Ltd. | 18 |
3 |
| Glaxo Group Limited | 4365 |
2 |
| F. Hoffmann-La Roche AG | 7839 |
2 |
| Abbott Laboratories | 2289 |
2 |
| Academia Sinica | 956 |
2 |
| Other owners | 106 |